We found for
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries
New Guidelines for Economic Evaluation in Germany and the United Kingdom: Are We Any Closer to Developing International Standards?
